Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure
Suzanne George(Dana-Farber Cancer Institute), Jean‐Yves Blay(Centre Léon Bérard), Paolo G. Casali(Fondazione IRCCS Istituto Nazionale dei Tumori), Axel Le Cesne(Institut Gustave Roussy), Patricia Stephenson(Rho (United States)), Samuel E. DePrimo(Pfizer (United States)), Charles S. Harmon(Pfizer (United States)), Calvin Law(Pfizer (United States)), Jeffrey A. Morgan(Dana-Farber Cancer Institute), Isabelle Ray‐Coquard(Centre Léon Bérard), Vanessa Tassell(Pfizer (United States)), D. P. Cohen(Pfizer (United States)), George D. Demetri(Dana-Farber Cancer Institute)
Cited by 367
Abstract
Related Papers
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer et al.|JNCI Journal of the National Cancer Institute|2000|15.7k
Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor
Michael C. Heinrich, Christopher L. Corless, George D. Demetri et al.|Journal of Clinical Oncology|2003|2.3k